Loading the section…

AUPH: financial statements from SEC — TradeAlmanac

AUPH

Aurinia Pharmaceuticals Inc: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Revenue	78M	77M	73M	70M	62M	60M	68M	57M
Cost of revenue	7M	—	8M	7M	9M	—	6M	9M
Research and development	7M	—	8M	7M	6M	—	3M	4M
Selling, general and administrative	22M	—	26M	26M	20M	—	42M	45M
Operating expenses	36M	—	44M	50M	41M	—	56M	59M
Operating income	41M	33M	30M	20M	22M	−2M	12M	−2M
Interest expense	—	—	—	—	—	—	—	1M
Pre-tax income	44M	—	32M	22M	24M	—	15M	1M
Income tax	10M	—	411,000	643,000	1M	—	457,000	756,000
Net income	34M	211M	32M	22M	23M	1M	14M	722,000
Earnings per share	0.26	1.60	0.24	0.16	0.17	0.01	0.10	0.01
Earnings per share, diluted	0.25	1.53	0.23	0.16	0.16	0.01	0.10	0.01
Weighted average shares	132M	—	132M	135M	139M	—	143M	143M
Weighted average shares, diluted	138M	—	136M	138M	143M	—	146M	144M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	41M	80M	73M	53M	66M	83M	37M	33M
Inventory	46M	46M	45M

Cash flow

Metric	31/03/2026	31/03/2025
Operating cash flow	33M	1M
Depreciation and amortisation	5M	5M
Share-based compensation	−866,000	−3M
Investing cash flow	−18M	31M
Share buybacks	36M	47M
Financing cash flow	−54M

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator